HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Non-Insulin Diabetes Medications

A growing arsenal of non-insulin diabetes medications is expanding therapeutic options beyond traditional insulin therapy. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant benefits in glycemic control while reducing cardiovascular risks. DPP-4 inhibitors offer a convenient oral alternative, particularly for patients seeking weight-neutral treatments. Recent advancements include combination therapies that target multiple metabolic pathways simultaneously, enhancing efficacy while minimizing side effects. Additionally, bile acid sequestrants, dopamine agonists, and amylin analogs provide novel mechanisms for improving insulin sensitivity. With continued research into incretin-based therapies and dual-agonist formulations, non-insulin medications are playing a crucial role in personalized diabetes management.

Committee Members
Speaker at Diabetes and Endocrinology 2025 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical Center, United States
Speaker at Diabetes and Endocrinology 2025 - F Buck Willis

F Buck Willis

IUHS School of Medicine, Saint Kitts and Nevis
Speaker at Diabetes and Endocrinology 2025 - Gretchen Holmes

Gretchen Holmes

Memorial Hospital at Gulfport, United States
Diabetes 2025 Speakers
Speaker at Diabetes and Endocrinology 2025 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes and Endocrinology 2025 - Amy Gutman

Amy Gutman

AdventHealth; Tough Love MD, United States
Speaker at Diabetes and Endocrinology 2025 - Paraskevi Theofilou

Paraskevi Theofilou

Hellenic Open University, Greece
Speaker at Diabetes and Endocrinology 2025 - Clifford Morris

Clifford Morris

Kihealth, United States
Tags

Submit your abstract Today

Watsapp